Harding, Rachel
Hutchinson, Ashley
Seitova, Alma
Arrowsmith, Cheryl
Edwards, Aled
2019-10-07
<p><strong>Project: </strong>Biophysical investigation of purified HTT protein samples</p>
<p><strong>Experiment: </strong>Purification of Q23 and Q54 HTT and HTT-HAP40 from Sf9 </p>
<p><strong>Date completed:­ </strong>2019/10/07</p>
<p><strong>Rationale: </strong>Purification of HTT and HTT-HAP40 Q23 and Q54 for different biophysical and functional analyses</p>
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
https://doi.org/10.5281/zenodo.3555378
oai:zenodo.org:3555378
Zenodo
https://zenodo.org/communities/labscribbles
https://zenodo.org/communities/sgc-opennotebook
https://zenodo.org/communities/openlabnotebooks
https://doi.org/10.5281/zenodo.3555377
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
huntington's disease
huntingtin
protein purification
Purification of Q23 and Q54 HTT and HTT-HAP40 from Sf9 2019/10/07
info:eu-repo/semantics/other